



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

November 21, 2024

Christian Behrenbruch  
Managing Director and Group CEO  
Telix Pharmaceuticals Limited  
55 Flemington Road  
North Melbourne, Victoria 3051, Australia

**Re: Telix Pharmaceuticals Limited**  
**Registration Statement on Form 20-F**  
**Exhibit No. 4.17**  
**Filed October 17, 2024**  
**File No. 001-42128**

Dear Christian Behrenbruch:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Craig Hilts